"Vast" overhaul of EU pharmacovigilance may mean higher industry fees
This article was originally published in Scrip
Executive Summary
The size of the task facing those responsible for implementing the new EU pharmaceutical legislation is now becoming clear, as work gets fully under way on the processes and guidelines that will have to be put in place.